Mereo BioPharma Group

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell MREO and other ETFs, options, and stocks.

About MREO

Mereo BioPharma Group Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. Its portfolio include Etigilimab (MPH-313), Alvelestat (MPH-966), Setrusumab (BPS-804), Navicixizumab (OMP-305B83), Acumapimod (BCT-197), and Leflutrozole (BGS-649). 

CEO
Denise Vera Scots-Knight
CEODenise Vera Scots-Knight
Employees
39
Employees39
Headquarters
London, Greater London
HeadquartersLondon, Greater London
Founded
2015
Founded2015
Employees
39
Employees39

MREO Key Statistics

Market cap
38.15M
Market cap38.15M
Price-Earnings ratio
-1.08
Price-Earnings ratio-1.08
Dividend yield
Dividend yield
Average volume
1.88M
Average volume1.88M
High today
$0.2587
High today$0.2587
Low today
$0.2325
Low today$0.2325
Open price
$0.253
Open price$0.253
Volume
1.15M
Volume1.15M
52 Week high
$3.05
52 Week high$3.05
52 Week low
$0.20
52 Week low$0.20

MREO News

TipRanks 3d
Mereo BioPharma Shareholders Approve All AGM Resolutions

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...

Analyst ratings

71%

of 7 ratings
Buy
71.4%
Hold
28.6%
Sell
0%

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.